Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ocuphire Pharma SG&A Expenses 2010-2024 | IRD

Ocuphire Pharma sg&a expenses from 2010 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
  
Ocuphire Pharma Annual SG&A Expenses
(Millions of US $)
2023 $12
2022 $7
2021 $8
2020 $3
2019 $2
2018 $7
2017 $7
2016 $6
2015 $6
2014 $6
2013 $5
2012 $3
2011 $4
2010 $6
2009 $3
Ocuphire Pharma Quarterly SG&A Expenses
(Millions of US $)
2024-06-30 $3
2024-03-31 $5
2023-12-31 $3
2023-09-30 $2
2023-06-30 $4
2023-03-31 $2
2022-12-31 $2
2022-09-30 $2
2022-06-30 $2
2022-03-31 $2
2021-12-31 $1
2021-09-30 $2
2021-06-30 $3
2021-03-31 $2
2020-12-31 $1
2020-09-30 $1
2020-06-30 $1
2020-03-31 $0
2019-12-31 $-2
2019-09-30 $1
2019-06-30 $1
2019-03-31 $2
2018-12-31 $2
2018-09-30 $2
2018-06-30 $2
2018-03-31 $2
2017-12-31 $2
2017-09-30 $2
2017-06-30 $2
2017-03-31 $2
2016-12-31 $2
2016-09-30 $1
2016-06-30 $2
2016-03-31 $1
2015-12-31 $1
2015-09-30 $2
2015-06-30 $2
2015-03-31 $2
2014-12-31 $2
2014-09-30 $1
2014-06-30 $2
2014-03-31 $1
2013-12-31 $1
2013-09-30 $1
2013-06-30 $1
2013-03-31 $1
2012-12-31 $-0
2012-09-30 $1
2012-06-30 $1
2012-03-31 $2
2011-12-31 $1
2011-09-30 $1
2011-06-30 $1
2011-03-31 $1
2010-12-31 $2
2010-09-30 $2
2010-06-30 $2
2010-03-31 $1
2009-12-31 $1
2009-09-30 $1
2009-06-30 $1
2009-03-31 $1
Sector Industry Market Cap Revenue
$0.000B $0.000B
Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.
Stock Name Country Market Cap PE Ratio
Fanhua (AIFU) China $0.086B 2.07
Top KingWin (WAI) China $0.008B 0.00
S&W Seed (SANW) United States $0.006B 0.00
Invo BioScience (NAYA) United States $0.004B 0.00